MAGELIA SIGNED
A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MAGELIA project word cloud
Explore the words cloud of the MAGELIA project. It provides you a very rough idea of what is the project "MAGELIA" about.
Project "MAGELIA" data sheet
The following table provides information about the project.
| Coordinator |
INOREVIA
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 2˙793˙000 € |
| EC max contribution | 1˙955˙100 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-08-01 to 2021-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INOREVIA | FR (PARIS) | coordinator | 1˙955˙100.00 |
Map
Project objective
Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform. After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market. To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round. The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGELIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MAGELIA" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)
ERGOVIAkinematix (2018)
New wearable measurement devices for Industry 4.0 based on gaming motion-capture system
Read More